Product nameAnti-Apolipoprotein A V/APOA5 antibody
See all Apolipoprotein A V/APOA5 primary antibodies
DescriptionGoat polyclonal to Apolipoprotein A V/APOA5
Tested applicationsSuitable for: ELISA, WBmore details
Species reactivityReacts with: Human
Predicted to work with: Baboon
- Human liver lysates
This product was previously labelled as Apolipoprotein A V
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Storage bufferpH: 7.30
Preservative: 0.02% Sodium azide
Constituents: 0.5% BSA, Tris buffered saline
Concentration information loading...
PurityImmunogen affinity purified
Purification notesPurified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide.
- Pathways and Processes
- Metabolic signaling pathways
- Lipid and lipoprotein metabolism
- Lipid metabolism
Our Abpromise guarantee covers the use of ab77358 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
WB: Use at a concentration of 0.3 - 1 µg/ml. Predicted molecular weight: 41 kDa.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
FunctionMinor apolipoprotein mainly associated with HDL and to a lesser extent with VLDL. May also be associated with chylomicrons. Important determinant of plasma triglyceride (TG) levels by both being a potent stimulator of apo-CII lipoprotein lipase (LPL) TG hydrolysis and a inhibitor of the hepatic VLDL-TG production rate (without affecting the VLDL-apoB production rate) (By similarity). Activates poorly lecithin:cholesterol acyltransferase (LCAT) and does not enhance efflux of cholesterol from macrophages.
Tissue specificityLiver and plasma.
Involvement in diseaseDefects in APOA5 are a cause of susceptibility to familial hypertriglyceridemia (FHTR)[MIM:145750].mFamilial hypertriglyceridemia is a common inherited disorder in which the concentration of very low density lipoprotein (VLDL) is elevated in the plasma. This leads to increased risk of heart disease, obesity, and pancreatitis.
Defects in APOA5 are a cause of hyperlipoproteinemia type 5 (HLPP5) [MIM:144650]. HLPP5 is characterized by increased amounts of chylomicrons and very low density lipoprotein (VLDL) and decreased low density lipoprotein (LDL) and high density lipoprotein (HDL) in the plasma after a fast. Numerous conditions cause this phenotype, including insulin-dependent diabetes mellitus, contraceptive steroids, alcohol abuse, and glycogen storage disease type 1A (GSD1A) [MIM:232200].
Sequence similaritiesBelongs to the apolipoprotein A1/A4/E family.
modificationsPhosphorylation sites are present in the extracelllular medium.
- Information by UniProt
- Apo-AV antibody
- ApoA-V antibody
- Apoa5 antibody
Anti-Apolipoprotein A V/APOA5 antibody (ab77358) at 0.3 µg/ml + human liver lysate in RIPA buffer at 35 µg
Predicted band size: 41 kDa
Observed band size: 38 kDa why is the actual band size different from the predicted?
ab77358 has not yet been referenced specifically in any publications.